利用核糖体RNA作为鲍曼不动杆菌疫苗开发的分子靶点

IF 3 Q2 PHARMACOLOGY & PHARMACY
Elijah Kolawole Oladipo, Glory Jesudara Oluwasanya, Esther Oluwadarasimi Adaramola, Gbemisola Omolara Morawo, Blessing Jephthah Oluwalemu, Victor Oluwatobi Afolabi, Praise Akanni, Joel Damilare Ajagbe, Oluwadara Hannah Ojo, Fikayo Deborah Olayiwola, Shalom Busayo Akintola, Chris Olamide Balogun, Emmanuel Pelumi Kolapo, Ayomiposi Isaiah Oshoneye, Stephen Feranmi Adeyemo, Boluwatife Ayobami Irewolede, Bamidele Abiodun Iwalokun, Oluwatosin Akinola Ajibade, Olatunji Matthew Kolawole, Olubukola Monisola Oyawoye, Julius Kola Oloke, Helen Onyeaka
{"title":"利用核糖体RNA作为鲍曼不动杆菌疫苗开发的分子靶点","authors":"Elijah Kolawole Oladipo,&nbsp;Glory Jesudara Oluwasanya,&nbsp;Esther Oluwadarasimi Adaramola,&nbsp;Gbemisola Omolara Morawo,&nbsp;Blessing Jephthah Oluwalemu,&nbsp;Victor Oluwatobi Afolabi,&nbsp;Praise Akanni,&nbsp;Joel Damilare Ajagbe,&nbsp;Oluwadara Hannah Ojo,&nbsp;Fikayo Deborah Olayiwola,&nbsp;Shalom Busayo Akintola,&nbsp;Chris Olamide Balogun,&nbsp;Emmanuel Pelumi Kolapo,&nbsp;Ayomiposi Isaiah Oshoneye,&nbsp;Stephen Feranmi Adeyemo,&nbsp;Boluwatife Ayobami Irewolede,&nbsp;Bamidele Abiodun Iwalokun,&nbsp;Oluwatosin Akinola Ajibade,&nbsp;Olatunji Matthew Kolawole,&nbsp;Olubukola Monisola Oyawoye,&nbsp;Julius Kola Oloke,&nbsp;Helen Onyeaka","doi":"10.1186/s43094-025-00853-z","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><i>Acinetobacter baumannii,</i> a nosocomial pathogen, has emerged as a major clinical threat due to its ability to resist a broad range of antibiotics, contributing to the increased morbidity and mortality in hospital settings. This characteristic of <i>Acinetobacter baumannii</i> as a multiple-drug resistant (MDR) organism poses a critical global health challenge, necessitating an urgent need for alternative therapeutic strategies, such as vaccine development, as a preventive measure. In this study, we employ the method of reverse vaccinology and immunoinformatic tools to design a novel rRNA-based vaccine targeting the 16S and 23S rRNA of <i>Acinetobacter baumannii.</i></p><h3>Results</h3><p>16S and 23S rRNA sequences of <i>Acinetobacter baumannii</i> were retrieved from the National Center for Biotechnology Information database (NCBI). The B and T cells’ epitopes were predicted from these retrieved sequences using bioinformatics tools. The epitopes generated were further analyzed for antigenicity, toxicity, and allergenicity. The epitopes that passed these screenings, including key structural elements, were used in the design of the vaccine. The vaccine constructs were further assessed for their physicochemical properties and dynamics. Structural modeling and molecular docking studies confirmed effective binding to Toll-like receptor 4 (TLR-4), while immune simulations demonstrated the potential to elicit robust and durable immune responses.</p><h3>Conclusions</h3><p>This study demonstrates the potential of reverse vaccinology and immunoinformatics approaches in designing a novel rRNA-based vaccine targeting the 16S and 23S rRNA of <i>Acinetobacter baumannii</i>. By identifying highly antigenic, non-toxic, and non-allergenic epitopes and incorporating them into a structurally optimized rRNA-based vaccine construct, we present a promising candidate capable of eliciting strong immune responses. However, limitations such as the unavailability of datasets, especially on the 5S rRNA region in the databases, are a roadblock that needs to be addressed.</p></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"11 1","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00853-z","citationCount":"0","resultStr":"{\"title\":\"Leveraging ribosomal RNA as a molecular target for vaccine development against Acinetobacter baumannii\",\"authors\":\"Elijah Kolawole Oladipo,&nbsp;Glory Jesudara Oluwasanya,&nbsp;Esther Oluwadarasimi Adaramola,&nbsp;Gbemisola Omolara Morawo,&nbsp;Blessing Jephthah Oluwalemu,&nbsp;Victor Oluwatobi Afolabi,&nbsp;Praise Akanni,&nbsp;Joel Damilare Ajagbe,&nbsp;Oluwadara Hannah Ojo,&nbsp;Fikayo Deborah Olayiwola,&nbsp;Shalom Busayo Akintola,&nbsp;Chris Olamide Balogun,&nbsp;Emmanuel Pelumi Kolapo,&nbsp;Ayomiposi Isaiah Oshoneye,&nbsp;Stephen Feranmi Adeyemo,&nbsp;Boluwatife Ayobami Irewolede,&nbsp;Bamidele Abiodun Iwalokun,&nbsp;Oluwatosin Akinola Ajibade,&nbsp;Olatunji Matthew Kolawole,&nbsp;Olubukola Monisola Oyawoye,&nbsp;Julius Kola Oloke,&nbsp;Helen Onyeaka\",\"doi\":\"10.1186/s43094-025-00853-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><i>Acinetobacter baumannii,</i> a nosocomial pathogen, has emerged as a major clinical threat due to its ability to resist a broad range of antibiotics, contributing to the increased morbidity and mortality in hospital settings. This characteristic of <i>Acinetobacter baumannii</i> as a multiple-drug resistant (MDR) organism poses a critical global health challenge, necessitating an urgent need for alternative therapeutic strategies, such as vaccine development, as a preventive measure. In this study, we employ the method of reverse vaccinology and immunoinformatic tools to design a novel rRNA-based vaccine targeting the 16S and 23S rRNA of <i>Acinetobacter baumannii.</i></p><h3>Results</h3><p>16S and 23S rRNA sequences of <i>Acinetobacter baumannii</i> were retrieved from the National Center for Biotechnology Information database (NCBI). The B and T cells’ epitopes were predicted from these retrieved sequences using bioinformatics tools. The epitopes generated were further analyzed for antigenicity, toxicity, and allergenicity. The epitopes that passed these screenings, including key structural elements, were used in the design of the vaccine. The vaccine constructs were further assessed for their physicochemical properties and dynamics. Structural modeling and molecular docking studies confirmed effective binding to Toll-like receptor 4 (TLR-4), while immune simulations demonstrated the potential to elicit robust and durable immune responses.</p><h3>Conclusions</h3><p>This study demonstrates the potential of reverse vaccinology and immunoinformatics approaches in designing a novel rRNA-based vaccine targeting the 16S and 23S rRNA of <i>Acinetobacter baumannii</i>. By identifying highly antigenic, non-toxic, and non-allergenic epitopes and incorporating them into a structurally optimized rRNA-based vaccine construct, we present a promising candidate capable of eliciting strong immune responses. However, limitations such as the unavailability of datasets, especially on the 5S rRNA region in the databases, are a roadblock that needs to be addressed.</p></div>\",\"PeriodicalId\":577,\"journal\":{\"name\":\"Future Journal of Pharmaceutical Sciences\",\"volume\":\"11 1\",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-08-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://fjps.springeropen.com/counter/pdf/10.1186/s43094-025-00853-z\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43094-025-00853-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-025-00853-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

鲍曼不动杆菌是一种医院病原体,由于其对多种抗生素具有耐药性,已成为一种主要的临床威胁,导致医院发病率和死亡率增加。鲍曼不动杆菌作为多重耐药(MDR)生物的这一特征对全球卫生构成了重大挑战,迫切需要开发替代治疗策略,如疫苗开发,作为一种预防措施。在本研究中,我们采用反向疫苗学方法和免疫信息学工具设计了一种针对鲍曼不动杆菌16S和23S rRNA的新型rRNA疫苗。结果从美国国家生物技术信息中心数据库(NCBI)检索到鲍曼不动杆菌的16s和23S rRNA序列。利用生物信息学工具从这些检索到的序列中预测B细胞和T细胞的表位。进一步分析产生的表位的抗原性、毒性和过敏原性。通过这些筛选的表位,包括关键的结构元素,被用于疫苗的设计。疫苗结构进一步评估其物理化学性质和动力学。结构建模和分子对接研究证实了与toll样受体4 (TLR-4)的有效结合,而免疫模拟显示了引发稳健和持久免疫反应的潜力。结论本研究证明了反向疫苗学和免疫信息学方法在设计针对鲍曼不动杆菌16S和23S rRNA的新型rRNA疫苗方面的潜力。通过鉴定高抗原性、无毒和非致敏性的抗原表位,并将其纳入结构优化的rrna疫苗构建中,我们提出了一种有希望的候选疫苗,能够引发强烈的免疫反应。然而,诸如数据集不可用等限制,特别是数据库中的5S rRNA区域,是需要解决的障碍。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Leveraging ribosomal RNA as a molecular target for vaccine development against Acinetobacter baumannii

Background

Acinetobacter baumannii, a nosocomial pathogen, has emerged as a major clinical threat due to its ability to resist a broad range of antibiotics, contributing to the increased morbidity and mortality in hospital settings. This characteristic of Acinetobacter baumannii as a multiple-drug resistant (MDR) organism poses a critical global health challenge, necessitating an urgent need for alternative therapeutic strategies, such as vaccine development, as a preventive measure. In this study, we employ the method of reverse vaccinology and immunoinformatic tools to design a novel rRNA-based vaccine targeting the 16S and 23S rRNA of Acinetobacter baumannii.

Results

16S and 23S rRNA sequences of Acinetobacter baumannii were retrieved from the National Center for Biotechnology Information database (NCBI). The B and T cells’ epitopes were predicted from these retrieved sequences using bioinformatics tools. The epitopes generated were further analyzed for antigenicity, toxicity, and allergenicity. The epitopes that passed these screenings, including key structural elements, were used in the design of the vaccine. The vaccine constructs were further assessed for their physicochemical properties and dynamics. Structural modeling and molecular docking studies confirmed effective binding to Toll-like receptor 4 (TLR-4), while immune simulations demonstrated the potential to elicit robust and durable immune responses.

Conclusions

This study demonstrates the potential of reverse vaccinology and immunoinformatics approaches in designing a novel rRNA-based vaccine targeting the 16S and 23S rRNA of Acinetobacter baumannii. By identifying highly antigenic, non-toxic, and non-allergenic epitopes and incorporating them into a structurally optimized rRNA-based vaccine construct, we present a promising candidate capable of eliciting strong immune responses. However, limitations such as the unavailability of datasets, especially on the 5S rRNA region in the databases, are a roadblock that needs to be addressed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
44
审稿时长
23 weeks
期刊介绍: Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信